What is the clinical evidence from this study?

Study design: Other. Population: severe ischemic cardiomyopathy (n=10). Intervention: Autologous skeletal myoblast transplantation. Primary outcome: Feasibility and safety.

What question did this study set out to answer?

To assess the feasibility and safety of autologous skeletal myoblast transplantation into myocardial scars among patients with severe ischemic cardiomyopathy.

September 14, 2026Journal of the American College of CardiologyOpen Access

Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction

Q: What are the key findings of this study?

Autologous skeletal myoblast transplantation in severe ischemic cardiomyopathy improved mean ejection fraction from 24% to 32% (P<0.02) and NYHA class (P<0.0001), but showed arrhythmogenic potential.

View Full Paper

Ask AI

Bookmark

Key result

Autologous skeletal myoblast transplantation improves LVEF ~8% in ischemic cardiomyopathy but shows arrhythmogenic risk.

n=10

Why the study?

Autologous skeletal myoblast transplantation feasibility and safety in severe ischemic cardiomyopathy with postinfarction scar had not been established.

Is autologous skeletal myoblast transplantation safe and feasible in patients with severe ischemic cardiomyopathy undergoing coronary bypass?

Population

10 patients with severe ischemic cardiomyopathy and postinfarction akinetic nonviable scar

Comparison

Autologous skeletal myoblast transplantation at time of coronary bypass surgery

Design

Phase I open-label trial with blinded echocardiographic analysis

Follow-up

Average 10.9 months

Authors

PMPhilippe MenaschéInserm AHAlbert HagègeHeart Failure & Transplant JVJean‐Thomas VilquinInserm

Discussion

Member takes

Implication

Autologous skeletal myoblast transplantation during coronary bypass is feasible and may improve left ventricular function in severe ischemic cardiomyopathy, but carries a significant arrhythmogenic risk.

Key Points

To assess the feasibility and safety of autologous skeletal myoblast transplantation into myocardial scars among patients with severe ischemic cardiomyopathy.
Phase I trial of 10 patients with severe left ventricular dysfunction (ejection fraction ≤35%), nonviable postinfarction scars confirmed via dobutamine echocardiography and 18-FDG PET, and indication for coronary bypass grafting.
Skeletal myoblasts were cultured from a thigh biopsy over an average of 16 days (mean 871 × 10⁶ cells obtained) and implanted into myocardial scar tissue during bypass surgery.
At a mean follow-up of 10.9 months, mean left ventricular ejection fraction increased from 24 ± 1% to 32 ± 1% (p < 0.02) and NYHA functional class improved from 2.7 ± 0.2 to 1.6 ± 0.1 (p < 0.0001).
Blinded echocardiographic analysis demonstrated improved systolic thickening in 63% (14 of 22) of cell-grafted scar segments.
Postoperative complications included delayed sustained ventricular tachycardia in 4 patients requiring internal cardioverter-defibrillator placement, one early death unrelated to cell transplantation, and one noncardiac death at 17.5 months.

Structured PICO

Is autologous skeletal myoblast transplantation safe and feasible in patients with severe ischemic cardiomyopathy undergoing coronary bypass?

Population

10 patients with severe ischemic cardiomyopathy, LVEF <= 35%, and a postinfarction akinetic scar requiring coronary bypass, followed for an average of 10.9 months.

Intervention

Autologous skeletal myoblast transplantation (average 871 x 10^6 cells, 86% myoblasts) implanted across the scar at the time of coronary bypass surgery.

Outcome

Feasibility and safetysafety

Limitations

arrhythmogenic potential
requires confirmation by randomized studies
Small sample size
Lack of a randomized control group

Cite This Study

Menasché et al. (2003) studied severe ischemic cardiomyopathy (n=10). Autologous skeletal myoblast transplantation was evaluated on Feasibility and safety. Autologous skeletal myoblast transplantation in severe ischemic cardiomyopathy improved mean ejection fraction from 24% to 32% (P<0.02) and NYHA class (P<0.0001), but showed arrhythmogenic potential.

synapsesocial.com/papers/6aa80fb6e023c7fc1dbba106 https://doi.org/10.1016/s0735-1097(03)00092-5

View Full Paper

Ask AI

Bookmark

Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider